ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,572.20
      0.09%
      US Tech 100
      19,870.20
      0.12%
      Dow Jones
      39,326.23
      -0.13%
      Brent Oil
      85.425
      -1.25%
      Bitcoin
      56,315.34
      0.84%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Amarin Corp PLC (AMRN) Quote

      Amarin Corp PLC

      Amarin Corp PLC (AMRN)

      NASDAQ
      0.7263
      -0.0102
      ( -1.38% )
      Updated: 14:12:28
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      0.7263
      Bid
      0.7263
      Ask
      0.7271
      Volume
      1,264,493
      0.72 Day's Range 0.7771
      0.00 52 Week Range 0.00
      Market Cap
      302.605M
      Previous Close
      0.7365
      Open
      0.75
      Last Trade
      3000
      @
      0.7263
      Last Trade Time
      14:12:28
      Financial Volume
      $ 949,873
      VWAP
      0.751189
      Average Volume (3m)
      -
      Shares Outstanding
      410,868,659
      Dividend Yield
      -
      PE Ratio
      -
      Earnings Per Share (EPS)
      -
      Revenue
      -
      Net Profit
      -

      About Amarin Corp PLC

      Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa. Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.amarincorp.com
      Headquarters
      London, Gbr
      Founded
      1970
      Amarin Corp PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMRN. The last closing price for Amarin was $0.74. Over the last year, Amarin shares have traded in a share price range of $ 0.00 to $ 0.00.

      Amarin currently has 410,868,659 shares outstanding. The market capitalization of Amarin is $302.60 million.

      AMRN Latest News

      More News

      Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

      -- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride...

      7 hours ago
      GlobeNewswire Inc.

      Form 8-K - Current report

      June 04 2024
      Edgar (US Regulatory)

      Amarin Board of Directors Announces CEO Transition

      -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE...

      June 04 2024
      GlobeNewswire Inc.

       Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

      -- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml...

      May 28 2024
      GlobeNewswire Inc.

      Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

      DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer...

      May 06 2024
      GlobeNewswire Inc.

       Amarin Reports First Quarter 2024 Business Update and Financial Results

      -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24...

      May 01 2024
      GlobeNewswire Inc.

      Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug...

      April 24 2024
      GlobeNewswire Inc.

      Amarin Announces Results of Annual General Meeting of Shareholders

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its...

      April 22 2024
      GlobeNewswire Inc.

      Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President...

      April 15 2024
      GlobeNewswire Inc.

      Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic...

      April 08 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SHPWShapeways Holdings Inc
      $ 0.540969
      (157.60%)
      		59.53M
      MORFMorphic Holding Inc
      $ 55.80
      (75.25%)
      		45.44M
      ZAPPZapp Electric Vehicles Group Ltd
      $ 6.975
      (71.38%)
      		65.81M
      VRPXVirpax Pharmaceuticals Inc
      $ 0.988
      (70.93%)
      		147.38M
      IVPInspire Veterinary Partners Inc
      $ 2.40
      (61.07%)
      		41.72M
      HLVXHilleVax Inc
      $ 1.785
      (-87.30%)
      		20.34M
      CLEUChina Liberal Education Holdings Ltd
      $ 0.666628
      (-69.42%)
      		12.7M
      WETHWetouch Technology Inc
      $ 2.29
      (-27.53%)
      		429.41k
      SYTSYLA Technologies Company Ltd
      $ 2.25
      (-25.99%)
      		451.57k
      CJETChijet Motor Company Inc
      $ 6.00
      (-25.93%)
      		148.11k
      MAXNMaxeon Solar Technologies Ltd
      $ 0.286
      (19.17%)
      		424.66M
      NVDANVIDIA Corporation
      $ 128.68
      (2.26%)
      		176.1M
      VRPXVirpax Pharmaceuticals Inc
      $ 0.988
      (70.93%)
      		147.38M
      TSLATesla Inc
      $ 251.065
      (-0.18%)
      		121.23M
      SVMHSRIVARU Holding Ltd
      $ 0.1997
      (25.68%)
      		104.47M

      AMRN Discussion

      View Posts
      L0tsaluck2000 L0tsaluck2000 17 minutes ago
      The amrn news on china is not showing up on the etrade news feed. how about others?
      👍️0
      JRoon71 JRoon71 1 hour ago
      Looks like the average price cut is 60% in China. Not sure what that price is based on. But it likely means a sub-$100 price point for Vazkepa, if approved for reimbursement.

      https://www.gtlaw.com/en/insights/2024/3/china-on-the-move-lessons-from-chinas-2023-national-negotiation-of-drug-prices
      👍️ 1
      JRoon71 JRoon71 1 hour ago
      Thanks for that Chromasome!
      👍️0
      ralphey ralphey 2 hours ago
      So all of China is worth minus 2 cents . If only Greenland would come on board then the stock would boom !
      👍️0
      seve333 seve333 2 hours ago
      Problem is many expected a couple catalyts to hit like they did and the stock to run. The buyback was going to goose the price as well after these catslyts. We just seem to keep moving the goalposts over and over again when things don't materialize. At this point anyone expecting brave to help the SP is delusional. The buyback will likely be used to get us in compliance now because nothing else is going to move it
      👍️0
      Chromosome Chromosome 2 hours ago
      There is private insurance in China but it’s expensive and usually used by ex-pats and very wealthy individuals. I would say 95%+ rely on government coverage
      👍️0
      JRoon71 JRoon71 2 hours ago
      DMC, how do you know that AMRN is being sold short, naked? Shorting is obviously not illegal, but I'm not sure how that translates to naked short selling.
      👍️ 1
      JRoon71 JRoon71 2 hours ago
      They are selling but do not have national reimbursement in place. So it is currently only being paid via private pay (not sure if private health insurance exists in China).
      👍️0
      Jasbg Jasbg 2 hours ago
      JR, That was all that my org. question to you was about - you confirming what you yourself suggested - at copy/paste - the Confirming mail from Brave research group here. I simply were interested to see the formulation in that letter - as this subject has been debated a lot here 'earlier.
      ---------------------------------------------------

      Then Sleven comes out aggressively attacking that I asked a simple question - do anyone know where Amarin stands in the delisting process (being under $1- for now some time). Why that coursed - for this 'nonsense debate' who knows.

      This self important guy sure has a short fuse - in his often provoking behavere.
      👍️0
      situ situ 3 hours ago
      Vascepa is already selling in China for high trigs so the reimbursement should already be in place.
      👍️0
      DMC8 DMC8 3 hours ago
      Filed.
      👍️ 1
      JRoon71 JRoon71 3 hours ago
      Zman, I agree. I am sure that there probably is an overarching strategy, but Sarissa, the Board, and management team don't share it. Hence, why we have to sit around speculating about next moves.
      👍️0
      Chromosome Chromosome 3 hours ago
      As a way to enter the global innovative drug market, the Chinese government has done a decent job honoring patents. However, they will squeeze you during the pricing negotiations and if priced too low, will have an effect on pricing in other markets. Merck and BMS decided not to accept pricing for Keytruda and Opdivo, and as a result their market share for these products that are share leaders in other markets is in the single digits. There will be a calculus to consider when negotiating and accepting Chinese government pricing proposal, namely impact on other markets. As others have said, this will be a volume game and they need to work on lowering their costs as much as possible.
      👍️ 1
      zmanindc zmanindc 3 hours ago
      It’s the lag from approval to reimbursements that keeps the stock from running. I am not sure how long until you see access to the wider Chinese market but the EU reimbursement rollout has been slow. In my opinion we need two other catalysts for the stock to run. The first is the anti trust BS suit which will cause a buyer to pause due to the legal risk. The second is to get wider reimbursement. Of course if Amarin were to actually come out with another version of V to win back the US then we could see some immediate improvement. I still don’t see any strategy with this company.
      👍️ 1
      rosemountbomber rosemountbomber 3 hours ago
      JRoon, you are exactly on the money. Approval means very, very little to the immediate economic viability of the company. Next is waiting for reimbursement, and then more time waiting for sales to materialize. It is all about dollars and cents and the bottom line, which unfortunately will take some time, with risks along the way so the market discounts all that.
      👍️ 1
      ziploc_1 ziploc_1 3 hours ago
      "According to a recent report on cardiovascular health and disease in China, cardiovascular disease (CVD) accounted for 44-47% of all death in urban and rural areas in China, meaning two out of every five deaths were due to CVD. It is estimated that 330 million patients suffer from CVD in China, and that China has one of the highest CVD death rates in the world.ii According to the World Heart Federation, cardiovascular events, such as ischemic heart disease and stroke, are projected to increase by 50 percent among the population in China between 2010 and 2030 (based on population aging and growth alone)."

      The main issues, which remain to be dealt with by Amarin...
      1. Will China rely on Vaskepa  fom Edding (via Amarin) to treat CVD....OR switch to a home grown EPA knock off to keep their costs down?
      2. Will China insist on prices too low for Amarin's Vaskepa to maintain profitability?
      3. How much lower will Amarin need to adjust worldwide prices for Vascepa...after agreeing to lower prices in China?

      China approval of Vascepa for CVD patients presents an impressive worldwide sales volume opportunity for Vascepa...but it also carries with it the aforementioned risks...
      in addition, it introduces the probablity of an AG for the U.S.
      👍️ 1
      JRoon71 JRoon71 4 hours ago
      I think we are well past the point of approvals really goosing the stock price. At this point, we need actual revenue to have a meaningful impact on the SP.

      I say this, because even with some of the approvals in the past (ie. Canada, UK, etc.), it has not translated into any meaningful revenue to Amarin. We have well over a dozen approvals around the world, with almost no revenue to show for it. So most analysts/institutional buyers probably look at Amarin as a "crying wolf" stock.

      As we see real revenue begin to flow in from Europe and China, the SP will naturally grow.

      I also think Italy, France, and Germany approvals will go a long way. Without them (or at least 2 of them), there is not as much value to a buyer.

      In other words, WS is no longer rewarding Amarin for "potential" like a Biotech startup with a big Phase 3 drug. They are treating Amarin like an ordinary company with a commercialized drug that now needs to show revenue.
      👍️0
      IgnoranceIsBliss IgnoranceIsBliss 4 hours ago
      You'd think we'd get a bigger reaction to getting both primary and secondary approval in a country with well over a billion people, half of whom probably die of CVD.

      It just goes to show you how investors just assume China will steal the drug and make/sell it cheap.
      👍️0
      lizzy241 lizzy241 4 hours ago
      Capt, good luck. a little side story. My brother lived in FL. I forget the name of the hurricane, but he was prepared. They filled the bathtub with ice and beer they were fine living in the BR and had water and beer!😂
      Hey they don't call you capt beer for nothing!
      👍️0
      ramfan60 ramfan60 4 hours ago
      https://finance.yahoo.com/news/amarin-partner-eddingpharm-receives-regulatory-113000810.html

      Looks like a press release
      👍️ 2 ☺️ 2
      Chromosome Chromosome 5 hours ago
      Thanks Zip…
      👍️0
      ziploc_1 ziploc_1 5 hours ago
      Chromosome..."Terms of the agreement( i.e. in 2015) include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens."

      With the anticipated large volume of Vaskapa sales in China, the sales base volume should reach $150 million briskly.

      As J.T. said..."Vascepa is a volume play...not a price play."
      👍️ 3
      JRoon71 JRoon71 5 hours ago
      Jasbg, that was not a "non-factual rumor". It was confirmed by one of the lead investigators, per my previous post.
      👍️0
      Jasbg Jasbg 5 hours ago
      Sleven, And you should likewise be embarrassed for starting 'the non factual' rumor 'Brave did not meet endpoint' - right.

      I guess that it why you 'out of the blue' starts attacking people - as so often before.
      👍️0
      Chromosome Chromosome 6 hours ago
      If I recall correctly, we are due 15 million milestone payment so should help with cash position too
      👍️0
      JRoon71 JRoon71 6 hours ago
      Bummer. Well, China is large, and hopefully they can at least get rolling with some private pay right away.

      Thanks Chromosome.
      👍️0
      Chromosome Chromosome 6 hours ago
      Sorry meant Jan 2025 inclusion….
      👍️0
      Chromosome Chromosome 6 hours ago
      Decisions for NRDL inclusion are made before July 1st for the following year. So in this case we missed the deadline for Jan 24 inclusion and the earliest we can expect inclusion is starting Jan 1 2026. The negotiation with the government itself takes a long time and while I hope this can move fast enough to make the 2026 timing, it could be as late as 2027. However, there is the OOP market that may be affordable to certain segment.
      👍️0
      Invest83838 Invest83838 6 hours ago
      Good Luck Capt!

      I am in Austin area so we are on "the dry side" of the hurricane and cussing that we will get no to little rain from it.

      I hope no tornadoes spawn from the hurricane and cause damage!
      👍️0
      Number sleven Number sleven 6 hours ago
      JRoon, From what I can find, the list is updated in December and implemented January first of the following year.
      Sleven,
      👍️0
      tke458 tke458 6 hours ago
      If nothing else, the value of the “asset” that is AMRN has increased. I’ll let the experts value that asset and Denner monetize that asset but today helps me feel better about the latter happening to my satisfaction
      👍️ 2
      zmanindc zmanindc 6 hours ago
      Here is a good article that explains the reimbursement process in China. It does not give a timeline but is thorough.

      https://search.app/1H9eVUYDJewWcKws9
      👍️0
      JRoon71 JRoon71 6 hours ago
      I'm curious when the NRDL is updated in China. It says they update it once per year. I assume it is based on calendar year, and if that's the case, hopefully we get reimbursement approval by year end so that it's included in their new pricing guide for 2025.
      👍️0
      Number sleven Number sleven 6 hours ago
      DAR, The shipments I track are US imports.
      Sleven,
      👍️0
      DAR53 DAR53 7 hours ago
      Capt, stay safe. You are no doubt having your issues with being on the south side of Houston (Clear Lake I think). I'm on the north side (Spring) and winds and rain are not too bad at this time. Put the raincoats on the dogs for their early pee and it didn't take them long to finish their busines and back under cover. LOL
      GL
      👍️0
      DMC8 DMC8 7 hours ago
      Eddingpharm will help to clear the inventories much quickly, much more significance than the royalties and profit-sharing.
      👍️0
      DAR53 DAR53 7 hours ago
      NS, that was my initial thought. But, I don't recall the shipping destination of those recent purchases of encapsulated product. Do you recall offhand?
      👍️0
      Triple88 Triple88 7 hours ago
      Credit Evila, I was just passing it along
      👍️0
      JRoon71 JRoon71 7 hours ago
      Jasbg, sorry I thought I posted it already. I did post this 6 months ago, but here it is again. This was the final e-mail in a string of e-mails I had with Carol van Hulle:

      I presented preliminary results in addition to the overall trial design. The preliminary results suggest that the trial may not meet its primary endpoint, which was an improvement in blood flow in the brain. However, that may change with the final analyses.

      Regards, Carol
      ---------------------------
      Dr. Carol Van Hulle, Pronouns: She, her, hers
      Department of Medicine
      School of Medicine and Public Health
      University of Wisconsin-Madison
      cavanhulle@wisc.edu
      👍️0
      Number sleven Number sleven 7 hours ago
      Jasbg, You should be embarrassed that you didn't know that a company your invested in is not in compliance with NASDAQ listing rules. Instead you respond with arrogance. Read more. Post less.
      Sleven,
      👍️ 1
      Number sleven Number sleven 7 hours ago
      TCI1, Great DD. Thanks for posting. I'll try to track the outcome.
      Sleven,
      👍️ 1
      DMC8 DMC8 7 hours ago
      Lets make Eddingpharm catalyst VIRAL!!!

      Eddingpharm’s huge catalyst need every shareholder’s help to publicize on every main stream financial medias, REDDIT.

      https://stocktwits.com/Bulltrader988/message/578742260
      👍️0
      Downtownguy Downtownguy 7 hours ago
      stay safe Capt.
      👍️0
      CaptBeer CaptBeer 7 hours ago
      The Eye of this hurricane is about to pass right over us now. The power is flickering and the dog needs to go out to pee. Oh boy this is fun! NOT.
      👍️0
      TCI1 TCI1 8 hours ago
      Credit Evila on Stocktwits:
      ITALY: Not sure if my interpretation of this document is correct, but VAZKEPA is on the “Agenda of reimbursement and pricing procedures at the Scientific-Economic Commission” being discussed this week (July 8th to 12th).
      Negotiation type: Variations in the regime of reimbursement.
      Duration process (provisional): 129 days.

      https://www.aifa.gov.it/documents/20142/2468753/ODG_CSE_del_8-9-10-11-12_luglio_2024_HTA.pdf
      👍️0
      Jasbg Jasbg 8 hours ago
      Sleven, You bloated again - as so often before. This has nothing to do with you what so ever (beside - as I recall you actually started the rumor 'Brave not successful' - and ended being very offended 'on everyone' ).
      --------------------------

      Post were for JR - offering the other day 'to place his mail here - with Brave researchers saying endpoint not met' - shouldn't be that hard to understand with your sharp sense of logic.
      👍️0
      Number sleven Number sleven 8 hours ago
      Triple, This might explain the recent purchase of encapsulated product.
      Sleven,
      👍️ 2
      Number sleven Number sleven 9 hours ago
      Triple, Nice find.
      Sleven,
      👍️ 1
      ziploc_1 ziploc_1 9 hours ago
      Triple...Great good news...Now we await important forthcoming announcements from Edding about reimbursements for Vascepa...as they talk with the NMPA (Chinese National Products Administration)....These developments could influence Vascepa prices worldwide and lead to an explosive growth in sales volumes.

      It could result in a lower number of shares in the $50 million buy back by Amarin being acquired...but that would be a small price to pay in view of the anticipated increased volume of sales of Vascepa worldwide.
      👍️ 1
      TCI1 TCI1 9 hours ago
      Great find. Maybe they don’t want to affect the SP while undertaking share buyback, but if it’s material they only have a set number of days to announce. There haven’t been any SEC filings since approval. I presume there will be a milestone payment due which will be welcome in Q3.
      👍️ 1

      Your Recent History

      NASDAQ
      AMRN
      Amarin
      BIT
      ECH3
      ETFS 3x Long CHF Short EUR
      Delayed Upgrade Clock